Fig 1: Schematic diagram of ECM1 in the development of heart failure. Increased ECM1 in patients with HF promotes cardiac fibrosis with elevated TGF-β1, CTGF and PICP through binding to LRP1. Therefore, the ECM1 plays an aggravating role in cardiac injury (elevated CK-MB and NT-proBNP) and HF (decreased LVEF) caused by Ang II
Fig 2: Correlation between serum ECM1 levels and serum biomarkers related to cardiac fibrosis in HF patients. Serum ECM1 is positively correlated with (A) TGF-β1, (B) CTGF, (C) PICP, and (D) LRP1. Spearman correlation analysis was performed
Fig 3: Comparison of serum ECM1 and LRP1 in control group and heart failure group. A Serum ECM1 levels were detected by ELISA in control subjects (n = 80) and heart failure (HF) patients (n = 93). B Serum LRP1 levels were detected by ELISA in control subjects (n = 80) and patients with HF (n = 93). C The ROC curve was used to obtain the optimal cut-off value of serum ECM1 (122.9 pg/mL) that distinguishes the HF patients from non-HF controls. The t-test was applied to compare the differences between two groups. ***P < 0.001 vs. the control group
Fig 4: Comparison of serum ECM1 and LRP1 in heart failure group according to cardiac function. A Serum ECM1 levels were detected by ELISA in HF patients with NYHA functional Class II (n = 38), NYHA functional Class III (n = 34) and NYHA functional Class IV (n = 21). B Serum LRP1 levels were detected by ELISA in HF patients with NYHA functional Class II (n = 38), NYHA functional Class III (n = 34) and NYHA functional Class IV (n = 21). One-way analysis of variance (ANOVA) was applied to compare the differences between three groups, followed by LSD post hoc analysis for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001 indicates significant differences
Supplier Page from Abcam for Human LRP1 ELISA Kit